Informations générales (source: ClinicalTrials.gov)
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
Interventional
Phase 3
Eli Lilly and Company (Voir sur ClinicalTrials)
juin 2020
janvier 2028
02 octobre 2025
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is
safe and effective for the intermittent acute treatment of migraine in children aged 6 to
17. The study will last about 12 months and may include up to 7 visits.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Julien NGO | 29/03/2024 01:29:15 | Contacter | ||
Critères
Tous
- Participants must have completed study H8H-MC-LAHX (NCT03988088) or study
H8H-MC-LAHV (NCT number to be determined)
- Participants must weigh at least 15 kilograms (kg)
Exclusion Criteria:
- Participants must not be pregnant or nursing
- Participants must not have any acute, serious, or unstable medical condition
- Participants must not be actively suicidal or at significant risk for suicide, in
the opinion of the investigator